Pharmaceuticals News and Research

RSS

FDA grants approval of nonprescription Sklice lotion to treat head lice infestations

Today, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.

27 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

New method for removing synthetic estrogen from water bodies

Synthetic estrogens from pharmaceuticals contaminate rivers and threaten the health of humans and fish.

21 Oct 2020

New DNA-cutting tool could advance gene editing for novel treatments

Gene editing for the development of new treatments, and for studying disease as well as normal function in humans and other organisms, may advance more quickly with a new tool for cutting larger pieces of DNA out of a cell's genome, according to a new study by UC San Francisco scientists.

21 Oct 2020

Life science sector is thriving in Northern Ireland

The growing importance of Northern Ireland’s pharmaceutical and life sciences industries is revealed today [Tuesday 20 October 2020] in a new report tracking the significant contribution the sector makes to the NI economy.

21 Oct 2020

Progressive group highlights Trump, Tillis weakness on insulin price tags

During the first presidential debate of 2020, President Donald Trump touted his efforts to curb skyrocketing drug prices and declared that insulin is now "so cheap, it's like water."

20 Oct 2020

New inhaled treatment may lead to self-administered therapy for COVID-19

An inhaled treatment against the SARS-CoV-2 virus may lead to a future self-administered therapy for COVID-19, the pandemic that has killed more than 1 million people worldwide.

20 Oct 2020

Experimental ALS drug shows potential to prolong patient survival

An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has now demonstrated the potential to also prolong patient survival.

16 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.

14 Oct 2020

New study may lead to more effective, personalized cancer immunotherapies

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

12 Oct 2020

New initiative identifies key parameters underlying effective anti-tumor immunity

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

9 Oct 2020

As Trump touts his ‘great’ COVID drugs, the pharma cash flows to Biden, not him

Pharmaceutical giants Regeneron and Gilead Sciences got the kind of publicity money can't buy this week after President Donald Trump took their experimental drugs for his coronavirus infection, left the hospital and pronounced himself fully recovered.

9 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

NTHU research could have significant impact on the treatment of dementia

One of the causes of neurodegenerative diseases such as Parkinson's and Alzheimer's is the calcification of the basal nucleus of the brain, which blocks the membrane protein channels on the surface of brain cells, preventing the transmission of signal molecules and nutrients to the cells.

8 Oct 2020